P1.01-37 BPI-9016M, a Novel C-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results From a First-In-Human, Phase 1, Dose-Escalation Study

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.593
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2017English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

Phase I Study of Capmatinib in MET‐positive Solid Tumor Patients: Dose Escalation and Expansion of Selected Cohorts

Cancer Science
Cancer ResearchMedicineOncology
2019English

Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology
Hematology
2010English

First-In-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-In-Class Dual MEK/RAF Inhibitor in Patients With Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2012English

Preliminary Results of a Phase 1 Dose Escalation Study of the First-In-Class Anti-Cd74 Antibody Drug Conjugate (Adc), Stro-001, in Advanced B-Cell Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy